Monopar
Wilmette
About Monopar
Monopar Therapeutics is an emerging biopharmaceutical company focused on developing orphan oncology compounds. Its lead compound, Hu-ATN-658, is a novel monoclonal antibody for the potential treatment of several deadly cancers. Hu-ATN-658 targets the urokinase plasminogen activator receptor (uPAR). Cancer Research UK will be conducting Hu-ATN-658’s early development, including a Phase I clinical trial. In 2014, Chandler D. Robinson, Christopher M. Starr, and Andrew P. Mazar founded the company in Wilmette, Illinois.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $196.3M
- Funding stage: IPO
- Last round: Post-IPO Equity (Sep 2025)
- Ticker: nasdaq:MNPR
- Website: monopartx.com
- Phone: (847) 388-0349
Industries & Categories
Biopharma, Biotechnology, Developer Tools, Health Care, Oncology
Social Profiles
Canonical: https://fsome.com/organization/monopar-47834 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.